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differently in rostral versus caudal cortical
neuroepithelium.
The transience of normal Fgf10 expres-
sionwould support the notion that only the
transition to radial glia is responsible for
the later increase in VZ and basal neural
progenitor cells. A definitive way to test
this would be to create a conditional
Fgf10 knockout mouse crossed to either
a BLBP or hGFAP-Cre mouse line, which
would delete Fgf10 after the neuroepithe-
lial transition to radial glia. Moreover,
FGF10 is expressed in the adult in areas
associated with new cell generation (Haji-
hosseini et al., 2008), so it would be worth
examining the impact of conditional
FGF10 loss at later stages. Do other Fgf
ligands, like Fgf7,which alsobinds Fgfr2b,
compensate for loss of Fgf10 and play
a role during normal neurogenesis? Addi-
tionally, conditional knockout of Fgfr2b
would tease out any multifunctional roles
this receptor may have throughout neuro-
genesis.
Given the importance of brain size to
normal function, identifying the specific
molecules that increase or decrease brain
elements is undeniably valuable. Clearly,
Fgfs need to be explored further in the
light of this study and prior work. There
are 22 Fgfs with four varied and spliced
receptors, and their unique spatial and
temporal expression patterns during brain
development are just beginning to be
examined. While bearing a humble name
for their effects on stimulating fibroblast
division, Fgfs were originally isolated
from the brain in the 1970s, and may
turn out to have their most interesting
effects in governing its creation.
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In addition to its role in glycolysis, GAPDH has been implicated as a mediator of neurotoxicity triggered
by nitrosative stress. In this issue of Neuron, Sen et al. identify a novel, negative regulator of this GAPDH
neurotoxic pathway termed GOSPEL, which, like GAPDH itself, is regulated by S-nitrosylation.Excess generation of reactive oxygen or
nitrogen species (ROS/RNS) is thought
to be a primary mediator of neuronal cell
injury and death in neurodegenerative
disorders. For example, nitric oxide (NO)
participates in neurodestructive eventsvia either formation of toxic peroxynitrite
as a result of reaction with superoxide
anion or S-nitrosylation of regulatory
protein groups. S-Nitrosylation is a redox
reaction, representing a covalent addition
of an NO group to a critical cysteine thiol/Neusulfhydryl (or more properly thiolate anion,
RS) to produce an S-nitrosothiol (SNO)
derivative. Such posttranslational modifi-
cation can modulate the function or
activity of target proteins to regulate
broad aspects of bodily and brainron 63, July 16, 2009 ª2009 Elsevier Inc. 3
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Previewsfunction, including synaptic plasticity,
neuronaldevelopment,proteinmisfold-
ing, and cell death (Lipton et al., 1993;
Hess et al., 2005; Nakamura and
Lipton, 2007). Recent research has
revealed that overproduction of NO
negatively affects neuronal survival by
S-nitrosylation of multiple substrates.
For example, S-nitrosylation of Parkin,
proteindisulfide isomerase (PDI), or dy-
namin relatedprotein 1 (Drp1)mediates
protein misfolding or excessive mito-
chondrial fission, both of which
contribute to the pathophysiology of
neurodegenerative disorders (Naka-
mura and Lipton, 2007; Cho et al.,
2009). The laboratory of Solomon
Snyder previously showed that S-nitro-
sylatedGAPDH(SNO-GAPDH) triggers
a nuclear signaling pathway leading to
cell death (Hara et al., 2005). GAPDH
is a well-known glycolytic enzyme
that plays a critical role in energy
production, but mounting evidence
suggests that GAPDH has multiple
functions; the proapoptotic activity of
nuclear GAPDH represents one such
alternative pathway. The Snyder
group had found that S-nitrosylation
imbues upon GAPDH the ability to
bind to the ubiquitin E3 ligase, Siah1,
which harbors a nuclear localization
signal (NLS), thereby escorting
GAPDH into the nucleus. GAPDH
then exerts its neurotoxic effects by
stabilizing Siah1, enabling the degra-
dation of nuclear substrates, such
as nuclear receptor corepressor (N-
CoR), via the ubiquitin E3 ligase
activity of Siah1 (Figure 1). Nuclear
GAPDH stimulates acetylation by
p300/CBP, which in turn induces acti-
vation of various target proteins,
including p53, to augment the cell
death pathway (Sen et al., 2008).
The SNO-GAPDH cascade may
play a role in the pathogenesis of
several neurodegenerative diseases.
Recent studies have shown in a cell
culture model of Huntington’s disease
(HD) thatmutant Huntingtin protein (mtHtt)
can form a ternary complex with GAPDH
and Siah1 (Bae et al., 2006). Although
mtHtt lacks an NLS,mtHtt can translocate
to the nucleus and produce neurotoxicity
in cell culture models (Martindale et al.,
1998). Reportedly, the mtHtt/SNO-
GAPDH/Siah1 complex translocates to
the nucleus, enabling mtHtt to contribute
to this toxicity (Bae et al., 2006). Support-
ing these findings, Senatorov et al. (2003)
found evidence for nuclear accumulation
of GAPDH in a transgenic model of HD.
Additionally, SNO-GAPDH may also
contribute to the pathophysiology of Par-
kinson’s disease (PD).
The drug R-()-deprenyl (selegi-
line), which may ameliorate the
progression of early-stage PD,
appears to prevent S-nitrosylation of
GAPDH both in cellular and animal
models of PD (Hara et al., 2006). It is
postulated that the binding of dep-
renyl to GAPDH interferes with the
formation of SNO-GAPDH and its
interaction with Siah1, thereby afford-
ing neuroprotection. Although these
prior studies raised the possibility
that the SNO-GAPDH pathway could
serve as a potential molecular target
for drug development, the precise
mechanism that controls the proa-
poptotic activity of SNO-GAPDH
remained elusive. The Snyder group
now reports in this issue of Neuron
that an endogenous inhibitor of the
SNO-GAPDH cascade provides neu-
roprotection by interfering with the
interaction between SNO-GAPDH
and Siah1 (Sen et al., 2009).
Snyder and colleagues performed a
yeast two-hybrid screen and identi-
fied a cytoplasmic, 52 kDa protein
that binds to the N terminus of
GAPDH. The protein, termed
GOSPEL, is highly expressed in skel-
etal muscle, liver, heart, and brain. In
brain, in situ hybridization revealed
high levels of GOSPEL in cerebellar
Purkinje cells and hippocampal
CA1-3 pyramidal and dentate granule
neurons; GAPDH also manifested
increased expression in these areas.
The amino acid sequence of GOSPEL
is remarkably preserved among
human, mouse, and rat, although
GOSPEL does not contain any known
functional domains. Binding of
GOSPEL to GAPDH is dependent
upon amino acids 160–200 in
GOSPEL and 80–120 in GAPDH.
Next, Sen et al. (2009) showed that
NO regulated the GOSPEL/GAPDH
interaction. One mechanism for NO
production in neurons in vivo involves
activation of N-methyl-D-aspartate
(NMDA)-type glutamate receptors. Stimu-
lation of NMDA receptors triggers Ca2+
influx, which in turn activates neuronal
NO synthase (nNOS) as well as the gener-
ation of ROS (Hara et al., 2005; Lipton,
2006) (Figure 1). Excessive activation of
NMDA receptors is implicated in neuronal
damage in many neurological disorders,
Figure 1. Possible Mechanism of S-Nitrosylated
GAPDH (SNO-GAPDH) and GOSPEL (SNO-
GOSPEL) Controlling Neuronal Cell Injury and
Death
(A) Low levels of NO can S-nitrosylate GOSPEL. NO prefer-
entially S-nitrosylates GOSPEL to form a SNO-GOSPEL/
GAPDH complex when NO levels are relatively low,
preventing GAPDH from interacting with Siah1.
(B) Excess generation of NO caused by excitotoxic stress
can S-nitrosylate both GOSPEL andGAPDH in the cytosol.
S-Nitrosylation of GAPDH promotes interaction between
GAPDH and Siah, allowing nuclear translocation of the
GAPDH-Siah1 complex. In the nucleus, the GAPDH/
Siah1 complex contributes to neuronal cell injury and
death.4 Neuron 63, July 16, 2009 ª2009 Elsevier Inc.
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injury to chronic neurodegenerative
diseases that include PD, HD, Alzheimer’s
disease, amyotrophic lateral sclerosis, and
HIV-associated dementia. In the current
study, Sen et al. found that NO produced
byactivationofNMDAreceptorsenhances
the formation of the GOSPEL/GAPDH
complex. S-Nitrosylation of GOSPEL,
GAPDH, or both facilitates interaction
between the two proteins. Notably,
NMDA induces the formation of SNO-
GOSPEL prior to the appearance of SNO-
GAPDH, indicating that the interaction of
SNO-GOSPEL and GAPDH precedes
that of SNO-GAPDH and Siah1. Because
of these temporal differences in sensitivity
to S-nitrosylation, the authors speculate
that the initial S-nitrosylation of GOSPEL
represents a protective effect of NO under
physiological conditions, while subse-
quent S-nitrosylation of GAPDH mediates
the detrimental action of NO under patho-
physiological conditions. S-Nitrosylation
of GAPDH facilitates binding to Siah1 and
consequent transport into the nucleus,
with deadly results for the cell.
Perhaps the most significant finding of
the study is the molecular mechanism by
which SNO-GOSPEL mediates neuropro-
tection. The authors conclude that SNO-
GOSPEL competes with Siah1 for binding
to (SNO)-GAPDH. Indeed, GOSPEL
mutants that cannot bind to GAPDH or
lack the nitrosylation site, thus decreasing
the binding affinity for GAPDH, fail to
protect neurons from NMDA insult. These
results further confirm the notion that
GOSPEL exerts its neuroprotective effect
by inhibiting the formation of the SNO-
GAPDH/Siah1 complex. The authors
further confirmed this conclusion by
showing that RNAi-mediated reduction
of endogenous GOSPEL increases
nuclear GAPDH translocation and subse-
quent neuronal cell death in response to
NMDA exposure. Additionally, the authors
found that this pathway is operative in vivo
in mouse brain by showing that lentiviral-
mediated delivery of GOSPEL, but not
its GAPDH-deficient binding mutant,
decreased injury caused by NMDA injec-
tion. Based on these findings, Sen et al.
concluded that they had discovered
GOSPEL as a new negative regulator of
the SNO-GAPDH cascade, capable of
enhancing neuronal survival in cell-based
and animal models of neurodegenerativedisease.TheSNO-GOSPEL/SNO-GAPDH
pathway may also be important in normal
aging, which is thought to be associated
with oxidative/nitrosative stress. Thus,
this new work characterizes a previously
unrecognized modulator of the SNO-
GAPDH cascade, providing novel insight
into RNS-mediated neuronal cell death.
For future work, several unanswered
questions remain. Why does SNO-
GOSPEL appear earlier than SNO-
GAPDH? The authors could not show
transfer of the NO group from GAPDH to
GOSPEL, arguing against transnitrosyla-
tion as the reason for the early appearance
of SNO-GOSPEL after NMDA exposure. A
possible reason for SNO-GOSPEL levels
increasing before SNO-GAPDH might
have to do with the rapidity and stability
of the covalent redox reaction producing
nitrosylation. For example, SNO may
form a very stable modification on
GOSPEL, thereby avoiding the fact that
NO is often a good ‘‘leaving group.’’ In
that case, NO might react with the target
cysteine (C47) on GOSPEL even though
the cytosolic concentration of NO is very
low. This can occur if the S-nitrosylated
cysteine shares pi electrons with a neigh-
boring tyrosine residue to chemically
stabilize the SNO group (Stamler et al.,
1997). Although there is no tyrosine
residue located near C47 in the primary
amino acid sequence of GOSPEL, its
three-dimensional structure by crystallog-
raphy or NMR is not yet known. S-Nitrosy-
lation of GOSPEL might also result in
a conformational change that not only
enhances its binding to GAPDH but also
reduces the accessibility of SNO to cyto-
solic reductants, such as glutathione or
denitrosylating enzymes, as recently sug-
gested by Jaffrey and colleagues (Paige
et al., 2008).
What are the implications of the new
work for neurodegenerative disorders?
Pesticides and other environmental toxins
that inhibit mitochondrial complex I are
thought to result in oxidative/nitrosative
stress and consequent aberrant protein
accumulation and cell death (Beal, 2001;
Nakamura and Lipton, 2007). In animal
models, administration of complex
I inhibitors, such as MPTP, 6-hydroxy-
dopamine, rotenone, or paraquat, which
results in overproduction of ROS/RNS,
reproduces many of the features seen in
sporadic PD, including dopaminergicNeneuronal degeneration, upregulation and
aggregation of a-synuclein, Lewy body-
like intraneuronal inclusions, and behav-
ioral impairments (Beal, 2001). Along
these lines, Sen et al. (2009) demonstrate
the presence of SNO-GOSPEL and SNO-
GAPDH inMPTP-treated mice, with SNO-
GOSPEL appearing first, thus mimicking
the in vitro results described above. Addi-
tionally, the authors showed that overex-
pressed GOSPEL reduced NMDA-medi-
ated brain injury. These findings suggest
that redox regulation of these proteins
may have pathophysiological relevance.
A future direction will be to determine
whether neuron-specific depletion of
GOSPEL by gene targeting can promote
neuronal cell death in vivo under neurode-
generative conditions associated with
generation of ROS/RNS. This type of
experiment will be particularly important
to strengthen the notion that GOSPEL
has neuroprotective activity in intact
animals.
Excessive nitrosative and oxidative
stress, possibly triggered by overactiva-
tion of NMDA receptors and mitochon-
drial dysfunction, may affect multiple
intracellular signaling pathways that could
conceivably contribute to neuronal cell
injury and death in ‘‘sporadic’’ cases of
neurodegenerative diseases. The eluci-
dation by Snyder and colleagues of a
pathway that leads to dysregulation of
GOSPEL/GAPDH binding by S-nitrosyla-
tion provides a mechanistic link between
free radical production and neuronal cell
injury in neurodegenerative disorders
such as PD and HD. Exploitation of the
redox pathways that influence these reac-
tions may lead to the development of new
therapeutic approaches to neurodegen-
erative conditions by controlling S-nitro-
sylation of specific proteins.
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In mammals, climbing fiber axons
synapses disappear from Purkinje
Neuron, Hashimoto et al. show that,
are already decided.
In mammals, large numbers of synaptic
partnerships are broken during early post-
natal life as a means of refining neural
circuits. A role for neural activity in this
process is well established. But how and
why some connections are maintained
while others are eliminated is not fully
understood. This process, known as
synapse elimination, has been found in
both the central and peripheral nervous
system. Studies in most parts of the brain
have been limited by the complexity,
variability, and inaccessibility of central
synapses. An exception, however, is the
cerebellum, where the emergence of the
one-to-one climbing fiber-to-Purkinje cell
association has long been appreciated.
In early life, climbing fiber axons form
highly branched collaterals with weak
perisomatic connections onto hundreds
of Purkinje cells (Sugihara, 2006). Each
Purkinje cell receives polyneuronal input
from a number of different climbing fibers.
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compete for sole innervation at eac
somata and appear in great number
by the time climbing fibers ascend t
This arrangement is transient with the
removal of all but oneof the climbing fibers
over the first several postnatal weeks in
rodents (Crepel et al., 1976). The transition
to single innervation occurs in stages. By
the end of the first postnatal week, climb-
ing fibers focus their synapses in ‘‘nests’’
around a subset of their initial Purkinje
cell targets. On each Purkinje cell, one
of these synaptic nests becomes 2- to
3-fold more powerful than the others
(Hashimoto and Kano, 2003). This skew-
ing becomes more extreme in the second
postnatal week because weaker inputs
completely disconnect. At roughly the
same time, however, other excitatory
(parallel fibers) and inhibitory inputs
(basket cells) make their first synapses
onto Purkinje cells (Hashimoto et al.,
2009b; Sotelo, 2008). The second post-
natalweek isalso theperiodwhenclimbing
fibers earn their name by growing upward
along the proximal dendritic shafts of
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h Purkinje cell. At the same time,
s on the dendrites. In this issue of
he dendrites, the winner and losers
Purkinje cells to extend their synaptic terri-
tory. Finally, in the third postnatal week,
synapse elimination is complete, and only
one climbing fiber remains. It establishes
hundreds of synapses distributed along
the proximal dendritic tree, while virtually
no climbing fiber synapses remain on the
soma (Cesa and Strata, 2009).
Despite the details outlined above,
relatively little is known concerning the
kinds of interactions that occur between
competing climbing fibers. For example,
do climbing fibers contend for the same
synaptic sites? Do they occupy spatially
segregated territories? Do all the inputs
climb the dendrites? To address the latter
question, Hashimoto et al. (2009a) devel-
oped new methods to assay positional
information about the synaptic sites of
individual axons.
To assess the distance of each climb-
ing fiber from the soma, the authors
measured rise times and delays of quantal
